Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

Comparison of Biological Therapies Following Combination Chemotherapy and Bone Marrow or Peripheral Stem Cell Transplantation in Women With Stage II or Stage III Breast Cancer

ClinicalTrials.gov ID: NCT00008203

Public ClinicalTrials.gov record NCT00008203. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jun 25, 2026, 12:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

High-Dose Chemotherapy Followed By Autologous Hematopoietic Stem Cell Support And One Of Two Regimens Aimed At Modifying Immune Reconstitution In Women With High Risk Stage 2 And Stage 3 Breast Cancer

Study identification

NCT ID
NCT00008203
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Herbert Irving Comprehensive Cancer Center
Other
Enrollment
Not listed

Conditions and interventions

Conditions

Interventions

  • aldesleukin Biological
  • recombinant interferon gamma Biological
  • carboplatin Drug
  • cyclophosphamide Drug
  • cyclosporine Drug
  • thiotepa Drug
  • autologous bone marrow transplantation Procedure
  • peripheral blood stem cell transplantation Procedure

Biological · Drug · Procedure

Eligibility (public fields only)

Age range
18 Years to 65 Years
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 30, 1996
Primary completion
Nov 30, 2005
Completion
Apr 30, 2008
Last update posted
Feb 3, 2013

1996 – 2008

United States locations

U.S. sites
1
U.S. states
1
U.S. cities
1
Facility City State ZIP Site status
Herbert Irving Comprehensive Cancer Center New York New York 10032

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00008203, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 3, 2013 · Synced Jun 25, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00008203 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →